Anaptysbio (ANAB) Current Leases (2020 - 2026)
Anaptysbio's (ANAB) quarterly Current Leases came in at $2.1 million in Q1 2026, up 8.05% YoY from $2.0 million in Q1 2025, and up 1.92% on a QoQ basis from $2.1 million in Q4 2025.
Anaptysbio (ANAB) Current Leases (2020 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 7 years of Current Leases data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Current Leases rose 8.05% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 8.05% YoY) and the FY2025 annual result came in at $2.1 million, up 8.05% from the prior year.
- Current Leases advanced to $2.1 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $2.1 million in Q1 2026 to a low of $1.5 million in Q1 2022.
- A 5-year average of $1.8 million and a median of $1.8 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases jumped 182.88% — and 2025, when it grew 8.05%.
- Tracing ANAB's Current Leases over 5 years: stood at $1.6 million in 2022, then rose by 8.55% to $1.8 million in 2023, then gained by 8.33% to $1.9 million in 2024, then climbed by 8.05% to $2.1 million in 2025, then advanced by 1.92% to $2.1 million in 2026.
- The last three Current Leases figures came in at $2.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.12 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 2.04 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 1.71 Mn |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 1.54 Mn |
| Dec 31, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.10 Mn |
| Jun 30, 2021 | 555,000.00 |